Department of Head and Neck, Division of Oral Surgery and Implantology, Institute of Clinical Dentistry, Catholic University of the "Sacred Heart", Gemelli Foundation for the University Policlinic, Rome.
Private practice, Ascoli Piceno, Italy; and.
J Craniofac Surg. 2022;33(5):1607-1613. doi: 10.1097/SCS.0000000000008319. Epub 2021 Oct 27.
The present study investigated clinical and histomorphometric data after sinus lift procedures performed with and without mesenchymal stem cells (MSCs) added to a graft. Twenty-four patients underwent maxillary sinus lift for implant placement. Twelve patients each were assigned to control (Group 1) and test (Group 2) groups. An MSC suspension was added to the graft used in patients of Group 2. Five of 12 patients in both groups underwent crestal-approach sinus lift with immediate implant placement, while seven patients received a lateral-approach sinus lift. The MSC suspension was obtained using the Rigenera protocol. Samples from the grafted site were evaluated, processed, and stained using three staining techniques 90 days after surgery. Histomorphometric analysis was performed using an imaging software (ImageJ). Two types of tissues were defined: Type 1 'mature bone' and Type 2 'osteoid tissue'. The mean Type 1 tissue percentage was 27.24% in Group 1 and 44.45% in Group 2 (P < 0.05). The mean Type 2 tissue percentage was 10.86% and 7.04% in Groups 1 and 2, respectively. The mean Type 1 tissue percentages for the crestal approach were 24.52% for Group 1 and 50.78% for Group 2, while the mean Type 1 tissue percentages for the lateral approach were 29.18% for Group 1 and 39.92% for Group 2. Patients treated with grafts containing MSCs showed 63.18% increased bone formation compared to those treated with grafts not containing MSCs (P < 0.05). Although our data showed a positive trend in patients treated with MSCs, differences between subgroups were not significant (P > 0.05).
本研究调查了在鼻窦提升术中加入间充质干细胞(MSCs)与不加入 MSCs 对移植后临床和组织形态计量学数据的影响。24 例患者接受了上颌窦提升以进行种植体植入。12 例患者每组分别被分配到对照组(第 1 组)和实验组(第 2 组)。第 2 组患者的移植中加入了 MSC 悬液。两组中各有 5 例患者采用了经牙槽嵴顶入路鼻窦提升伴即刻种植,7 例患者采用了经侧壁入路鼻窦提升。MSC 悬液是使用 Rigenera 方案获得的。术后 90 天,对移植部位的样本进行了评估、处理和使用三种染色技术染色。使用成像软件(ImageJ)进行了组织形态计量学分析。定义了两种组织类型:1 型“成熟骨”和 2 型“类骨质组织”。第 1 组的平均 1 型组织百分比为 27.24%,第 2 组为 44.45%(P<0.05)。第 1 组和第 2 组的平均 2 型组织百分比分别为 10.86%和 7.04%。第 1 组经牙槽嵴顶入路的平均 1 型组织百分比为 24.52%,第 2 组为 50.78%,第 1 组经侧壁入路的平均 1 型组织百分比为 29.18%,第 2 组为 39.92%。与未接受 MSC 治疗的患者相比,接受含有 MSC 的移植物治疗的患者的骨形成增加了 63.18%(P<0.05)。尽管我们的数据显示接受 MSC 治疗的患者有积极的趋势,但亚组之间的差异没有统计学意义(P>0.05)。